Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RVNC | US
0.03
0.58%
Healthcare
Biotechnology
30/06/2024
04/10/2024
5.22
5.25
5.34
5.01
Revance Therapeutics Inc. a biotechnology company engages in the development manufacture and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines moderate or severe dynamic forehead lines and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop manufacture and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems Inc. and changed its name to Revance Therapeutics Inc. in April 2005. Revance Therapeutics Inc. was incorporated in 1999 and is headquartered in Nashville Tennessee.
View LessLow Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
47.1%1 month
42.8%3 months
190.9%6 months
149.3%-
-
12.30
-3.79
0.99
-2.26
3.26
-0.64
-192.06M
543.82M
543.82M
-
-52.79
-
20.20
-2.10K
1.38
8.41
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.90
Range1M
1.58
Range3M
4.06
Rel. volume
0.53
Price X volume
13.35M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.42 | 593.84M | 0.95% | n/a | 50.92% |
Oculis Holding AG Ordinary shares | OCS | Biotechnology | 13.2 | 551.04M | 8.20% | n/a | 1.19% |
Pharming Group N.V. | PHAR | Biotechnology | 8.04 | 545.40M | -0.74% | n/a | 63.43% |
UroGen Pharma Ltd | URGN | Biotechnology | 12.7 | 534.85M | 0.95% | n/a | 326.69% |
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 9.97 | 518.14M | -2.92% | n/a | 2.32% |
Third Harmonic Bio Inc. | THRD | Biotechnology | 12.52 | 514.54M | -0.71% | n/a | 1.40% |
SIGA Technologies Inc | SIGA | Biotechnology | 6.98 | 498.16M | 0.87% | 5.95 | 0.97% |
CorMedix Inc | CRMD | Biotechnology | 8.9 | 497.15M | 7.62% | n/a | 1.29% |
Emergent BioSolutions Inc | EBS | Biotechnology | 9.35 | 494.68M | 1.74% | n/a | 226.97% |
KalVista Pharmaceuticals Inc | KALV | Biotechnology | 11.36 | 490.93M | -4.05% | n/a | 3.62% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.26 | 0.76 | Cheaper |
Ent. to Revenue | 3.26 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 12.30 | 14.10 | Par |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 190.88 | 74.67 | Riskier |
Debt to Equity | -3.79 | -1.82 | Cheaper |
Debt to Assets | 0.99 | 0.26 | Expensive |
Market Cap | 543.82M | 3.73B | Emerging |